Stay tuned and follow the latest
developments and news in Molecular Oncology.
In the context of the 29th Hellenic Congress of Clinical Oncology (29th ESKO) held on April 5-8, 2023 in Athens at the Athenaeum Intercontinental Hotel, Genekor played an active role. […]
Read More
The outcome of the Study was that information obtained from genetic analysis, especially from an integrated NGS analysis such as WES and WGS, is valuable for the diagnosis and individualized […]
Read More
The new publication of the Genekor Scientific Team on: CNV and RNA analysis reveal a germline pathogenic duplication of MSH2 exon 15 in a family with Lynch syndrome: A case […]
Read MoreOn Monday, January 16th, Nature Medicine published the first results of the observational study (GALAXY study), which is one of the 3 arms of the prospective study (CIRCULATE Japan). Important […]
Read More
Nikos Tsoulos, CEO of Genekor I.A.E., gave an interview to THE DOCTOR magazine on the importance of genetic testing in relatives of people who have been diagnosed with breast and […]
Read More
The study by the Genekor Scientific Team on “ The study by the Genekor Scientific Team on “Polygenic Risk Score in a cohort of 105 Breast Cancer patients previously tested […]
Read More
More than 7,000 rare diseases that affect more than 300,000,000 people around the world have been identified in recent years. This fact causes the need to use particularly innovative diagnostic […]
Read MoreAnother important study by the Genekor Scientific Team on “Next Generation Sequencing (NGS) for the identification of PARP inhibitors’ predictive biomarkers” was presented by Dr. Floros Ir. Theofanis (Oncologist Pathologist, […]
Read More
The study by the Genekor Scientific Team on “Cascade genetic testing utilized only in 31% of initial families with pathogenic variants in breast cancer genes” was presented at ESMO CONGRESS […]
Read More